poisar

Stocks · News reference

Barclays Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $650

BenzingaJul 24, 2026, 3:18 PMBenzinga Newsdesk

Barclays analyst Luke Sergott maintains Thermo Fisher Scientific (NYSE:TMO) with a Overweight and raises the price target from $625 to $650.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 24, 2026, 3:18 PM
Checked
Jul 24, 2026, 3:18 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAug 27, 2026, 5:00 PMDelveinsight

    Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

    The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

    Read original at globenewswire-inc
  2. Globenewswire IncAug 27, 2026, 3:00 PMSns Insider

    Laboratory Informatics Market to Grow from USD 4.08 Billion in 2025 to USD 6.69 Billion by 2035, at a CAGR of 5.06% - SNS Insider

    The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

    Read original at globenewswire-inc